Put Options

7 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.21 - $3.48 $14,807 - $23,316
6,700 New
6,700 $21,000
Q1 2024

May 15, 2024

SELL
$3.08 - $5.02 $51,128 - $83,332
-16,600 Reduced 80.19%
4,100 $12,000
Q4 2023

Feb 14, 2024

BUY
$2.85 - $4.19 $58,140 - $85,476
20,400 Added 6800.0%
20,700 $80,000
Q3 2023

Nov 14, 2023

SELL
$2.97 - $3.87 $2,673 - $3,483
-900 Reduced 75.0%
300 $0
Q2 2023

Aug 14, 2023

SELL
$3.0 - $5.97 $18,600 - $37,014
-6,200 Reduced 83.78%
1,200 $3,000
Q1 2023

May 15, 2023

BUY
$3.86 - $5.0 $5,790 - $7,500
1,500 Added 25.42%
7,400 $31,000
Q4 2022

Feb 14, 2023

BUY
$3.78 - $5.81 $22,302 - $34,279
5,900 New
5,900 $25,000

Others Institutions Holding ANIX

About Anixa Biosciences Inc


  • Ticker ANIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,661,700
  • Market Cap $78.5M
  • Description
  • Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the...
More about ANIX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.